Quality Assessment in Supportive Care in Head and Neck Cancer

Bonomo, Pierluigi; Paderno, Alberto; Mattavelli, Davide; Zenda, Sadamoto; Cavalieri, Stefano; Bossi, Paolo

doi:10.3389/fonc.2019.00926

Cited by 13 publications

(7 citation statements)

References 96 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Whatever happens, it's clear that the fear of falling badly sick again and spending days in hospital is something that consciously or unconsciously besets me and probably all surviving patients with cancer." are confronted with numerous, profound disabilities owing to the anatomical complexity of the head and neck region, which can also affect patients' families 225 . Swallowing and speech impairments occur in ~50% of HNSCC survivors following radiotherapy treatment and are often present long term 226 .…”

Section: Box 1 | Patient Experiencementioning

confidence: 99%

Head and neck squamous cell carcinoma

Johnson

Burtness

Leemans

et al. 2020

Nat Rev Dis Primers

2,230

1,926

View full text Add to dashboard Cite

Most head and neck cancers are derived from the mucosal epithelium in the oral cavity, pharynx and larynx and are known collectively as head and neck squamous cell carcinoma (HNSCC). Oral cavity and larynx cancers are generally associated with tobacco consumption, alcohol abuse or both, whereas pharynx cancers are increasingly attributed to infection with human papillomavirus (HPV), primarily HPV-16. Thus, HNSCC can be separated into HPV-negative and HPV-positive HNSCC. Despite evidence of histological progression from cellular atypia through various degrees of dysplasia, ultimately leading to invasive HNSCC, most patients are diagnosed with late-stage HNSCC without a clinically evident antecedent pre-malignant lesion. Traditional staging of HNSCC using the tumour-node-metastasis system has been supplemented by the 2017 AJCC/UICC staging system, which incorporates additional information relevant to HPV-positive disease. Treatment is generally multimodal, consisting of surgery followed by chemoradiotherapy (CRT) for oral cavity cancers and primary CRT for pharynx and larynx cancers. The EGFR monoclonal antibody cetuximab is generally used in combination with radiation in HPV-negative HNSCC where comorbidities prevent the use of cytotoxic chemotherapy. The FDA approved the immune checkpoint inhibitors pembrolizumab and nivolumab for treatment of recurrent or metastatic HNSCC and pembrolizumab as primary treatment for unresectable disease. Elucidation of the molecular genetic landscape of HNSCC over the past decade has revealed new opportunities for therapeutic intervention. Ongoing efforts aim to integrate our understanding of HNSCC biology and immunobiology to identify predictive biomarkers that will enable delivery of the most effective, least-toxic therapies.

show abstract

Section: Box 1 | Patient Experiencementioning

confidence: 99%

Head and neck squamous cell carcinoma

Johnson

Burtness

Leemans

et al. 2020

Nat Rev Dis Primers

2,230

1,926

View full text Add to dashboard Cite

show abstract

“…Given the complex of anatomical structure and daily functions in the head and neck area, HNSCC patients would face disabilities, so much as losing working ability, which can also affect families [24]. Thus, we are committed to exploring new treatment options, in order to increase the choice of treatments methods and construct prognosis model for HNSCC patients.…”

Section: Discussionmentioning

confidence: 99%

Development and Validation of an Individualized Immune Prognostic Signature in HNSCC

Sun

Zhao

et al. 2022

Preprint

View full text Add to dashboard Cite

Head and neck cancer is the seventh most common type of cancer worldwide, and the development of immunotherapy is conducive to the preservation of function and the improvement of prognosis. Based on immune gene database ImmPort and InnateDB, we investigated prognostic value of 546 head and necks squamous cell carcinoma samples from The Cancer Genome Atlas. We intersected of the two databases, selected specific module by WGCNA, and then performed univariate and multivariate Cox regression analyses to screen their prognostic roles in HNSCC patients. Three prognostic immune genes were identified as prognostic gene, including DEFB1, PTX3and SEMA3G. According to the risk scores of patients, we divided HNSCC patients into low- and high-risk subgroups by the median value of risk scores in each dataset. In addition, we calculated immune cells and immune infiltration of the two groups and constructed K-M survival curve plot based on immune infiltration result. Enrichment analysis indicated that cytokines and cytokine receptors interaction was more common in the specific immune gene module. Moreover, we constructed a nomogram based on the results of multivariate cox analysis and clinical information and confirmed the survival of the two groups by using two GEO database. We also established a correlation analysis between immune prognostic signature genes and immune checkpoints. Finally, we believed that PTX3 was the key gene, and the expression levels of PTX3 in 30 clinical samples was detected by immunohistochemical method. In conclusion, PTX3 is a key immune gene, which may contribute to poor prognosis of HNSCC by affecting TME.

show abstract

“…Despite various treatments, the longterm prognosis of TSCC is poor, and the 5 year survival rate is about 50% [6]. The survivors also have many severe disabilities, such as swallowing and speech disorders [7,8]. Therefore, nding effective targeted therapeutic molecules to TSCC is urgently needed.…”

Section: Introductionmentioning

confidence: 99%

TRAIP enhances progression of tongue squamous cell carcinoma through EMT and Wnt/β-catenin signaling by interacting with DDX39A

Liu,

Wang,

Guo

et al. 2024

Preprint

View full text Add to dashboard Cite

Background Tongue squamous cell carcinoma (TSCC) is one of the most common malignant tumors with high mortality and poor prognosis. Its incidence rate is increasing gradually. Tumor necrosis factor receptor-associated factor interacting protein (TRAIP), as a factor related to several tumors, reveals that its gene expression is different between normal tissue and primary tumor of head and neck squamous cell carcinoma using bioinformatics analysis. Method In our study, TCGA database, immunohistochemistry, proliferation assay, colony formation, wound healing assay, Transwell, cell cycle analysis and tumor xenografts model were used to determine the expression and functions of TRAIP in TSCC. Result We found that TRAIP may promote the proliferation, migration and invasion of TSCC. Furthermore, the results of bioinformatics analysis, mass spectrometry and co-immunoprecipitation suggested that DDX39A may be a TRAIP interacting protein. DDX39A has been proven to be an oncogene in several tumors, which may have an important effect on cell proliferation and metastasis in multiple tumors. In addition, the high expression of DDX39A implies the poor prognosis of patients. Our study demonstrated that TRAIP probably interact with DDX39A to regulate cell progression through epithelial-mesenchymal transition and Wnt/β-catenin pathway. Conclusion These results indicate that TRAIP is important in occurrence and development of TSCC and is expected to become the new promising therapeutic target.

show abstract

Quality Assessment in Supportive Care in Head and Neck Cancer

Cited by 13 publications

References 96 publications

Head and neck squamous cell carcinoma

Head and neck squamous cell carcinoma

Development and Validation of an Individualized Immune Prognostic Signature in HNSCC

TRAIP enhances progression of tongue squamous cell carcinoma through EMT and Wnt/β-catenin signaling by interacting with DDX39A

Contact Info

Product

Resources

About